Navigation Links
Did Eli Lilly Turn Wily With Regard to Their Best-selling Schizophrenia Drug?

Eli Lilly, the pharmaceutical company, is in a tight spot, defending its position against the law suits from mentally ill patients//, about the company’s best-selling schizophrenia drug, Zyprexa. The company is being blamed for undermining the health risks of the drug, which is being linked to obesity and high blood sugar.

On the basis of many supporting documents and internal communication between managers in the company, ample evidence has surfaced, that the company has indeed kept under wraps, the harmful side-effects of the drug Zyprexa.

Even the company’s published statistics which the sales representatives have been tutored to make light of, portrays statistics that about 30% of the patients consuming Zyprexa, have gained 22 pounds within a year of consuming the drug and some have gained as much as 100 pounds. The documents clearly portray the abiding worry of the company that its sales might plummet if they were honest about the drug’s effect on weight gain or blood sugar levels.

The company has not taken the allegation lightly and has completely denied it. Lilly explained that the FDA has been enabled with a clear picture of all the clinical trials and reviews regarding the usage of the drug world-wide. But documents in circulation within the company relates to an entirely different story. Apprehension regarding the drug’s side effects has been debated as early as 1999, to the extent that company bigwigs felt it could jeopardize the sales of their most popular product, if it were publicized.


AV
'"/>




Page: 1

Related medicine news :

1. Animal insulin product to be discontinued by drug major Eli Lilly
2. Eli Lilly Releases Digital Insulin Pen
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Changing Trends Regarding Insurance Cover For Weight Reduction Surgery
5. Leeches Provide Clues Regarding The Prevention Of Heart Disease
6. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
7. Mixed Opinion Regarding Common Medical And Engineering Entrance Test
8. Adolescents Influenced By Maternal Attitude Regarding Weight Control
9. Reforms Required With Regard To Mental Health Facilities
10. Tension between MP And the Cancer Council Head Regarding Screening Test for Male Cancer
11. A Just Published Book Promises To Guide Women Regarding Their Frequent UTI’
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... 2017 , ... EpiGentek , a Farmingdale, NY-based biotech ... methylation “gold rush” with their established portfolio of optimized assay kits that measure ... m6A , RNA methylation has received a new burst in interest as ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office accelerates ... National Capital has added 10 new sales professionals over the past 6 months and ... 15 additional new hires over the course of 2017. , “This new office ...
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to ... responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat ... which proposes a tax on prescription opioids to fund drug rehabilitation and prevention ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce ... large subjects. The ELITE DXA has an active scan window, which is more than ... to fit in the scan area could not undergo an accurate total body bone density ...
(Date:3/24/2017)... , ... March 24, 2017 , ... Digital Scientists, a ... to announce the opening of a Greenville, South Carolina location. The lab ... progress in Greenville. , “We’ve been working with South Carolina clients for years from ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 On Friday, benchmark ... Composite closed the trading session up 0.19%; the Dow ... 500 was down 0.08%. US markets made broad based ... day in green. Pre-market today, Stock-Callers.com reviews these four ... (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... , March 27, 2017 Arena Pharmaceuticals, Inc. ... on developing novel, small molecule drugs across multiple therapeutic areas, ... Chief Executive Officer, will present a corporate update at the ... 3:40pm ET.  The conference will take place April 4-5, 2017 ... New York , NY.  A live ...
Breaking Medicine Technology: